New targeted pill takes on Hard-to-Treat cancers with IDH mutations
NCT ID NCT04521686
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About 200 participants will receive the drug alone or combined with chemotherapy or another drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3410738 (an oral drug that targets IDH1 and IDH2 mutations)
What this could lead to
If successful, this could lead to a new targeted treatment option for people with advanced solid tumors that have specific IDH1 or IDH2 mutations.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is not yet known if the drug works. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Gustave Roussy
Villejuif, 94805, France
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
-
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, 33076, France
-
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515, Japan
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic of Scottsdale
Phoenix, Arizona, 85054, United States
-
Memorial Sloan Kettering Cancer Center
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Cancer Center
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Cancer Center
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
National Cheng-Kung Uni. Hosp.
Tainan, 704, Taiwan
-
National University Hospital
Singapore, 669606, Singapore
-
Osaka University Hospital
Suita-shi, Osaka, 565-0871, Japan
-
Prince of Wales Hospital
Hong Kong, Shatin, New Territories, Hong Kong
-
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea
-
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Shizuoka Cancer Center
Nakatogari, Shizuoka, 411-8777, Japan
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
The John Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
USC Norris Cancer Hospital
Los Angeles, California, 90033, United States
-
University of Chicago Pritzker School of Medicine
Chicago, Illinois, 60637, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States